Sativex, a Medicinal Cannabis Spray, has been approved in New Zealand

Stuart SchlossmanAlternative therapies and devices for Multiple Sclerosis (MS)

November 4, 2010

New Zealand medicines regulators have approved a cannabis-based spray for use by multiple sclerosis (MS) patients in this country, says a big manufacturer, GW Pharmaceuticals.
Its Sativex treatment for the relief of spasticity in MS patients contains two cannabinoids or active ingredients – THC and CBD, and is the first cannabinoid medicine derived from whole plant extracts from the cannabis sativa plant.
New Zealand’s was the fourth approval for Sativex following positive decisions in the UK, Spain and Canada, GW research director Stephen Wright said in a statement.
“We are delighted that Sativex has received positive endorsement from another of the world’s most highly regarded regulatory authorities”.

***********************************************************
Providing You with ‘MS Views and News’is what we do
Keep Informed and uptodate with information concerning
 Multiple Sclerosis when registered at
****************************************************************
Disclaimer:  ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews